Tafasitamab – March 2026

Powder for I.V. infusion 200 mg

  • Brand names:
    • Minjuvi®
  • Pharmaceutical Company:
    • SPECIALISED THERAPEUTICS ALIM PTY LTD
  • Condition/Indication: Relapsed and/or refractory follicular lymphoma (FL)
  • Meeting Date: March 2026
Public Summary Documents
Related Public Summary Documents
Last updated
11 March 2026